Novartis data highlight benefit of early treatment initiation in patients with secondary progressive multiple sclerosis (SPMS)

Data from Phase III EXPAND trial, continue to build on existing clinical evidence that Mayzent has significant impact on reducing the risk of disease progression, including physical disability and cognitive decline for patients with SPMS.

Read more